HF outcomes in SGLT2 inhibitor outcome trials in patients with T2D

Overview of heart failure information in patients with T2D and data from SGLT2 inhibitor CVOTs and cardio–renal trials.

Heart failure outcomes in SGLT2 inhibitor outcome trials in patients with T2D
Rate this content
  • Heart failure outcomes in SGLT2 inhibitor outcome trials in patients with T2D
  • HF outcomes in SGLT2 inhibitor outcome trials in patients with T2D
  • HF outcomes in SGLT2 inhibitor outcome trials in patients with T2D
  • HF is a common comorbidity in patients with T2D
  • Diabetes is associated with a worse prognosis in patients with HF
Do you want to go to the Presentation Builder section to create a new presentation?
Cancel Go